Agamree access in India: the CDSCO Rule 36 named-patient pathway
How families in India legally obtain Agamree (vamorolone) for pediatric Duchenne muscular dystrophy from US or EU source supply through CDSCO personal importation, with weight-based dosing logistics and ambient-temperature handling built into the case plan.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Agamree (vamorolone) is a first-in-class dissociative steroidal anti-inflammatory drug developed as an alternative to prednisone and deflazacort in Duchenne muscular dystrophy (DMD). It is formulated as an oral suspension at 40 mg per millilitre and was approved by the US Food and Drug Administration on 26 October 2023 for DMD in patients 2 years of age and older, with European Commission approval following in December 2023 and a CHMP positive opinion to expand the EU label down to age 2 issued on 27 April 2026. India has a very large DMD patient population by absolute numbers, and pediatric neuromuscular centres at AIIMS, Christian Medical College Vellore, Kokilaben, and Apollo Chennai regularly identify boys for whom families want the corticosteroid-class agent with the better bone, growth, and behaviour profile than prednisone or deflazacort. Agamree is not registered in India as of this review, and Indian families with cash means reach it through the Central Drugs Standard Control Organization (CDSCO) personal importation framework under Rule 36 of the Drugs and Cosmetics Rules 1945, with the Form 12A application and Form 12B permit issued by the office of the Drugs Controller General of India (DCGI). Reserve Meds coordinates the US-side or EU-side specialty sourcing through Catalyst Pathways or Santhera's local agent network, ambient-temperature logistics with no-freeze handling, and the documentation kit your pediatric neuromuscular specialist needs to file.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Reserved for you.
How Agamree reaches patients in India
Agamree (vamorolone oral suspension 40 mg/mL, FDA-approved 26 October 2023 for Duchenne muscular dystrophy in patients aged 2 years and older, per the FDA label at accessdata.fda.gov) does not appear on the Central Drugs Standard Control Organization SUGAM approved-product search at cdscoonline.gov.in as of 2026-06-01. Families access the drug under the Permission to Import Small Quantities of New Drug for Personal Use, statutory Form 12-B Permit applied for via Form 12-A under Rules 36 and 36A of the Drugs and Cosmetics Rules 1945 read with the New Drugs and Clinical Trials Rules 2019, with the pathway page at cdsco.gov.in. Applications are filed online through the SUGAM portal at cdscoonline.gov.in/CDSCO/Drugs_Personal. CDSCO public materials describe Form 12-B issuance on a priority basis typically within one to two working days once documentation is complete, an administrative practice rather than a gazetted service-level agreement. Where a hospital is the importer-of-record for a named patient under treatment, the parallel pathway is the Import Licence for Personal Use in CT Form-16 under the Second Schedule and Table-1 of the New Drugs and Clinical Trials Rules 2019, rules text at cdsco.gov.in/Acts-and-rules/New-Drugs. Form 12-B is single-consignment; chronic-therapy families re-file Form 12-A per shipment cycle, conventionally up to a three-month supply per permit. A registered medical practitioner with current National Medical Commission registration must sign the prescription specifying drug name, strength, dosage form, and total quantity required, alongside a treating physician's medical justification or case summary and a pro-forma invoice from the foreign supplier.
Where Agamree is dispensed in India
Agamree is an oral suspension shaken before each dose and administered once daily with food, with weight-based dosing at 6 mg/kg/day in paediatric DMD patients. Dispensing nodes are paediatric neurology and neuromuscular clinics rather than infusion suites. The Indian Centres of Excellence under the National Policy for Rare Diseases 2021 framework, identified in the policy document at mohfw.gov.in NPRD 2021, host the most-frequent paediatric DMD case load. Centres relevant to a vamorolone case include the All India Institute of Medical Sciences New Delhi Department of Paediatrics and Centre for Genetics and Inherited Metabolic Disorders, at aiims.edu; Christian Medical College Vellore Clinical Genetics and Paediatric Neurology service, at clin.cmcvellore.ac.in; the Postgraduate Institute of Medical Education and Research Chandigarh Genetic Metabolic Diseases unit; Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow Medical Genetics department; the Centre for DNA Fingerprinting and Diagnostics Hyderabad; King Edward Memorial Hospital Mumbai Paediatric Genetics service; and Indira Gandhi Institute of Child Health Bangalore. Private tertiary centres frequently involved in named-patient orphan imports include Kokilaben Dhirubhai Ambani Hospital Mumbai, Apollo Hospitals Chennai and Hyderabad, Fortis Memorial Research Institute Gurugram, and Medanta The Medicity Gurugram. The dispensing facility must hold a valid drug licence covering imported unregistered medicines.
What Agamree costs in India
The US wholesale acquisition cost for Agamree 40 mg/mL is approximately USD 9,500 per 100 mL bottle per Catalyst Pharmaceuticals public price disclosures, with annual acquisition costs reported in published cost analyses in the range of USD 400,000 to USD 500,000 per patient per year at typical paediatric DMD weight bands; the FDA label dosage section at accessdata.fda.gov label confirms the 6 mg/kg/day dose with a 300 mg/day cap at or above 50 kg of body weight. No public local-currency benchmark for Agamree in INR is observed on the National Pharmaceutical Pricing Authority ceiling-price database at nppaindia.nic.in as of 2026-06-01, consistent with the drug not being CDSCO-registered; do not estimate. Price snapshot: 2026-06-01. Cost layers on top of drug cost include international ambient-temperature freight (Agamree does not require refrigeration but freezing must be avoided), CDSCO permit and customs processing (nominal relative to drug cost), the dispensing hospital's drug-handling fee, and the Reserve Meds concierge fee itemised separately on every firm quote. Goods and Services Tax on life-saving medicines is set at 5 percent. The 3-month opened-bottle stability window at room temperature aligns reasonably well with quarterly shipping cadence for many weight bands; the weight-based recalculation cadence at every 3 to 6 months is a natural point to resize per-shipment volume.
Funding and access barriers for Agamree in India
The National Policy for Rare Diseases 2021 framework caps central financial assistance at INR 50 lakh per patient for treatment at designated Centres of Excellence under the Rashtriya Arogya Nidhi umbrella scheme; programme page at mohfw.gov.in RAN page. DMD is listed as a Group 3a rare disease under the policy. The cap is structured around one-time or short-course treatments and does not naturally align with the indefinite chronic dosing pattern of a corticosteroid-alternative agent, a point widely understood by NPRD coordinators at the designated CoEs. The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana hospitalisation cover of INR 5 lakh per family per year carries a limited specialty-drug package list and is not the operating financial structure for unregistered paediatric imports. Indian private insurers including Star Health, Niva Bupa, HDFC ERGO Health, Care Health, and ManipalCigna do not publish a standard rule for unregistered named-patient imports; IRDAI has not issued a uniform formulary rule for this category. India's out-of-pocket health expenditure share sits around 50 percent per the Ministry of Health and Family Welfare National Health Accounts series at nhsrcindia.org, and for unlicensed paediatric orphan imports the dominant funding pattern is family self-pay supplemented by diaspora remittance, crowdfunding through Ketto, Milaap, and ImpactGuru, and pharma compassionate-access programmes where the manufacturer operates one. Foreign Contribution (Regulation) Act 2010 considerations may apply if a foreign foundation or diaspora organisation is the named donor; a family paying directly is generally not engaged.
Recent regulatory and access news for Agamree
The CDSCO Notifications feed at cdsco.gov.in/Notifications remains the operational reference for any patient-facing change in the Form 12-A / 12-B regime; no drug-specific CDSCO notification for vamorolone over the last 12 months has been observed as of 2026-06-01. The Ministry of Health and Family Welfare has continued quarterly Health Minister's Committee updates on the National Policy for Rare Diseases list of approved Centres of Excellence and disease coverage, ministry page at mohfw.gov.in, with no Agamree-specific listing change observed in the most recent published roster. On the manufacturer side, Catalyst Pharmaceuticals and Santhera have continued regional rollout reporting for vamorolone through 2025 and 2026 quarterly disclosures; India-specific registration filings have not appeared on the SUGAM approved-product search at cdscoonline.gov.in as of the snapshot date.
Where Reserve Meds fits in Agamree cases
Reserve Meds is a US-based concierge coordinator. We do not replace your pediatric neuromuscular specialist, do not replace CDSCO or the DCGI, and do not replace the dispensing hospital pharmacy or the licensed specialty importer. What we do is orchestrate the US-side sourcing of Agamree through Catalyst Pathways' authorised specialty pharmacy network (or, where appropriate, EU-side sourcing through Santhera's local agents), ambient-temperature logistics with no-freeze handling and documented temperature logging through a bonded pharmaceutical 3PL, and the documentation kit your pediatric specialist needs for the Form 12A filing. No prior Reserve Meds case experience exists for Agamree as of this review, so standard NPP coordination applies with particular attention to weight-based dose recalculation at every pediatric checkup, the 3-month opened-bottle stability window, family training on the calibrated oral dosing syringe and the shake-before-each-dose requirement, and multilingual support where Hindi or Arabic is the family's working language. A single named coordinator carries the case from intake through the indefinite chronic dosing arc.
Next step
If an Indian child with confirmed DMD has a pediatric neuromuscular specialist considering Agamree, start your case at the portal. We will respond within 24 to 48 hours with a documentation kit for your specialist and an indicative cost range scaled to the child's current weight.
Reserved for you.
This guide is informational, not medical or legal advice. The named-patient framework requires a licensed Indian physician's clinical judgment; Reserve Meds is the coordinator, not the prescriber.